Urogen Pharma Ltd
URGN20.200USD
-0.420-2.04%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
933.22MCap. mercado
PérdidaP/E TTM
Más Datos de Urogen Pharma Ltd Compañía
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Información de Urogen Pharma Ltd
Símbolo de cotizaciónURGN
Nombre de la empresaUrogen Pharma Ltd
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoMs. Elizabeth A. (Liz) Barrett
Número de empleados235
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección9 Ha'ta'asiya St
CiudadRA'ANANA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIsrael
Código postal4365007
Teléfono97297707601
Sitio Webhttps://www.urogen.com/
Símbolo de cotizaciónURGN
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoMs. Elizabeth A. (Liz) Barrett
Ejecutivos de Urogen Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
24.21M
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
24.21M
0.00%
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
Otro
68.76%
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
Otro
68.76%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
29.41%
Research Firm
21.32%
Investment Advisor/Hedge Fund
20.22%
Investment Advisor
17.19%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.10%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
309
45.30M
97.92%
-6.91M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RTW Investments L.P.
4.54M
9.82%
+709.10K
+18.49%
Jun 30, 2025
TD Securities, Inc.
3.19M
6.9%
+1.44M
+82.40%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.33M
5.04%
+2.33M
--
Aug 05, 2025
Jefferies LLC
2.20M
4.75%
+1.38M
+169.90%
Jun 30, 2025
Soleus Capital Management, L.P.
2.19M
4.72%
+2.19M
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.11M
4.56%
-34.56K
-1.61%
Jun 30, 2025
SilverArc Capital Management, LLC
2.02M
4.37%
+641.32K
+46.43%
Jun 30, 2025
Pontifax Venture Capital
1.49M
3.21%
-1.00
-0.00%
Mar 14, 2024
Morgan Stanley & Co. LLC
1.47M
3.19%
+1.27M
+633.13%
Jun 30, 2025
Arkin Communication, Ltd.
1.37M
2.96%
--
--
Feb 22, 2024
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
ARK Israel Innovative Technology ETF
2.13%
Tema Oncology ETF
1.43%
ALPS Medical Breakthroughs ETF
0.55%
Hypatia Women CEO ETF
0.19%
iShares Micro-Cap ETF
0.16%
Vanguard US Momentum Factor ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
Ver más
ARK Israel Innovative Technology ETF
Proporción2.13%
Tema Oncology ETF
Proporción1.43%
ALPS Medical Breakthroughs ETF
Proporción0.55%
Hypatia Women CEO ETF
Proporción0.19%
iShares Micro-Cap ETF
Proporción0.16%
Vanguard US Momentum Factor ETF
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.1%
iShares Biotechnology ETF
Proporción0.07%
Fidelity Enhanced Small Cap ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
